[Carotinoid retinopathy. III. Reversibility].
Twenty-five patients (erythropoietic protoporphyria 23, polymorphous light eruption 1, "cosmetics" 1) were re-examined 2-10 months after therapy with beta-carotene and canthaxanthine was discontinued. Dark adaptation and ERG parameters had normalized, whereas crystalline retinopathy and pigment epithelial defects showed no signs of reversibility.
D016644:Canthaxanthin; D002338:Carotenoids / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004596:Electroretinography; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D010787:Photosensitivity Disorders / Q000188:drug therapy*; D011164:Porphyrias / Q000188:drug therapy*; D011166:Porphyrins / Q000097:blood*; D011524:Protoporphyrins / Q000097:blood*; D012164:Retinal Diseases / Q000139:chemically induced*; D012871:Skin Diseases / Q000188:drug therapy*; D019207:beta Carotene
D004338:Drug Combinations; D011166:Porphyrins; D011524:Protoporphyrins; D019207:beta Carotene; D002338:Carotenoids; D016644:Canthaxanthin; C041347:phenoro
Carotinoid-Retinopathie. III. Reversibilität.